NJ-PMC-GROUP
14.3.2023 10:46:43 CET | Business Wire | Press release
Paritosh M. Chakrabarti, business owner, author and philanthropist, today announced PMC Group and The Chakrabarti Foundation have made a sizeable donation of land and property to the Ramakrishna Mission Saradapitha Belur Math of West Bengal.
“Contributing to the Ramakrishna Mission Saradapitha is an honor. The Mission enshrines the teachings of India’s greatest spiritual leader and unifier of humanity, Swami Vivekananda,” explained Paritosh Chakrabarti. “This gift is a way for me to further those ideals. I am appreciative to Belur Math for accepting the donation. These gifts are also part of the ‘soul’ of PMC Group that I describe in my upcoming book, The Makings of PMC Group – A Corporation with a Soul."
The donation includes the notable Bose House which has been witness to many historical events and carries memories of great patriots and revolutionaries, the surrounding land, and a significant financial gift. The financial gift will provide for 1.) construction and development of two museum rooms, each housing panel exhibition-cum-photo galleries, manuscripts, rare and valuable collections and potentially, a multimedia presentation depicting the lives, activities, and legacies of Swami Vivekananda and Netaji Subhas Chandra Bose, 2.) production of cultural and educational activities to promote inter-cultural and inter-religious harmony and, 3.) installation of a commemorative plaque stating: “This historic Bose House Property has been donated by Paritosh M. Chakrabarti and Srimati Chakrabarti to Ramakrishna Mission Saradapitha, Belur Math for the Construction and Development of a Cultural and Educational Center to Promote the legacy of Swamiji and Netaji”.
The chairman of Rishra Municipality, Vijay Sagar Mishra said, “It’s a matter of great joy and honor for all of us to watch the handing over ceremony of Rishra Bose House to Ramakrishna Mission Saradapitha Belur Math. Converting it to a museum will bring the common people closer to the works and activities of the great patriot Netaji Subhas Chandra Bose and Swami Vivekananda. The present generation must be made aware of the glorious history so that they can take lessons from it and go ahead in serving the motherland.”
ABOUT PMC
PMC Group, owned by Paritosh M. Chakrabarti and his family, is a US based growth oriented, diversified, global chemicals and pharmaceuticals company dedicated to innovative solutions to every need in a broad range of end markets including, plastics, consumer products, electronics, coatings, packaging, mining, personal care, food, automotive and pharmaceuticals. The Company was built on a sustainable model of growth through innovation while promoting social good. PMC operates from a global manufacturing, innovation, and marketing platform with facilities in the Americas, Europe, and Asia. More information about PMC Group and its activities around the world can be found at www.pmc-group.com.
ABOUT THE CHAKRABARTI FOUNDATION
The Chakrabarti Foundation is a non-profit organization dedicated to promoting education around the world and believes excellence in education is a primary requirement for enduring civilization. To learn more please visit https://pmc-group.com/chakrabarti-foundation.
ABOUT RAMAKRISHNA MISSION SARADAPITHA BELUR MATH
Ramakrishna Mission Saradapitha Belur Math is a well-known and reputed philanthropic organization serving the society of India and abroad irrespective of caste, color, creed, religion, nationality, gender, regional bias, etc., through its vast network of nearly more than 250 branch-centers in the fields of education, culture, religion, health, relief and rehabilitation, rural and tribal development, publications, teachings and preaching and a large number of allied areas all of which are for the all-around development of the individual and the society as a whole. More can be found at https://belurmath.org/ramakrishna-mission-saradapitha-belur.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005278/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
